+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 55Years +
All Genders
ID05282550

Study of Trazodone to Improve Sleep and Memory in Early Alzheimers Disease with Mild Cognitive Impairment

Led by Johns Hopkins University · Updated on 2026-06-17

100

Participants Needed

1

Research Sites

48 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of trazodone on sleep quality, memory related to the hippocampus, and brain activity in people with Amnestic Mild Cognitive Impairment aMCI who have sleep complaints. The study aims to see if trazodone can increase total sleep time and the time spent in deep sleep stages known as Slow Wave Sleep SWS. This is a phase 2, randomized, placebo-controlled, double-blind crossover trial involving 100 participants. Participants will receive 50 mg of trazodone at bedtime for 4 weeks, followed by a 4-week washout period, then 4 weeks of placebo, or vice versa. This crossover design allows each participant to serve as their own control. The 4-week washout period is planned to fully clear trazodone from the body before switching treatments. During the study, participants will be assessed for changes in total sleep duration, SWS duration and intensity, sleep onset latency, sleep fragmentation, and self-reported sleep quality using the Pittsburgh Sleep Quality Index and Epworth Sleepiness Score. Memory performance and hippocampal brain activity during memory tasks will also be measured. These assessments take place from baseline through up to 12 weeks. Safety and ability to undergo MRI scans are monitored as well.

CONDITIONS

Brief Title

Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone

Research Team

B

Barry Greenberg, PhD

P

Paul Rosenberg, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here